Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Dasotraline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 04 Jan 2018 Planned End Date changed from 28 Feb 2018 to 28 Apr 2018.
- 04 Jan 2018 Planned primary completion date changed from 28 Feb 2018 to 28 Apr 2018.
- 09 Aug 2017 Status changed from not yet recruiting to recruiting.